Attached files
| file | filename |
|---|---|
| 10-K - 10-K - PLURISTEM THERAPEUTICS INC | zk1110396.htm |
| EX-31.1 - EXHIBIT 31.1 - PLURISTEM THERAPEUTICS INC | exhibit_31-1.htm |
| EX-23.1 - EXHIBIT 23.1 - PLURISTEM THERAPEUTICS INC | exhibit_23-1.htm |
| EX-14.1 - EXHIBIT 14.1 - PLURISTEM THERAPEUTICS INC | exhibit_14-1.htm |
| EX-10.5 - EXHIBIT 10.5 - PLURISTEM THERAPEUTICS INC | exhibit_10-5.htm |
| EX-32.1 - EXHIBIT 32.1 - PLURISTEM THERAPEUTICS INC | exhibit_32-1.htm |
| EX-32.2 - EXHIBIT 32.2 - PLURISTEM THERAPEUTICS INC | exhibit_32-2.htm |
| EX-31.2 - EXHIBIT 31.2 - PLURISTEM THERAPEUTICS INC | exhibit_31-2.htm |
| EX-10.2 - EXHIBIT 10.2 - PLURISTEM THERAPEUTICS INC | exhibit_10-2.htm |
Exhibit 10.8
Summary of Directors Ongoing Compensation
As of June 30, 2011 our non-executive officer directors receive cash compensation as follows:
|
·
|
Annual compensation of $12,500;
|
|
·
|
Meeting participation fee of $935 per in-person meeting; and
|
|
·
|
For meeting participation by telephone, $435 per meeting.
|
If the compensation is paid in New Israeli Shekels (“NIS”), the exchange rate of the directors’ fees used to calculate the fees will be not less then $4.25 per NIS.
The directors are also entitled to two and a half percent (2.5%) from amounts received by us from non diluting funding and strategic deals.